Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes
1Coronary Care Unit, The Johns Hopkins Hospital, Baltimore, Md 21287, USA. sschulm@jhmi.edu
Insights
Acute coronary syndromes, often caused by plaque rupture, require effective antiplatelet therapies like aspirin and others. Understanding individual responses to these treatments is crucial for optimizing patient care and future research.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) are a leading cause of hospitalization in patients with coronary artery disease.
- The underlying pathology frequently involves atherosclerotic plaque rupture or fissure, leading to platelet aggregation.
Observation:
- Platelet aggregation plays a critical role in the pathophysiology of ACS.
- Several large randomized trials have evaluated three main classes of antiplatelet agents: aspirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors.
Findings:
- A comprehensive understanding of the risks and benefits associated with these antiplatelet therapies is essential for effective ACS management.
- Significant interpatient variability exists in responses to antiplatelet medications.
Implications:
- Optimizing ACS treatment requires careful consideration of individual patient responses to antiplatelet drugs.
- Further research is needed to address the variability in antiplatelet therapy response and improve patient outcomes.
Abstract:
Acute coronary syndromes are a frequent cause of hospital admission for patients with coronary artery disease. The pathophysiology of acute coronary syndromes often involves plaque rupture or fissure with platelet aggregation. Recognition of the importance of platelet aggregation resulted in several large randomized trials testing 3 types of platelet antagonists, aspirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors. A thorough understanding of the data, risks, and benefits of these therapies is important to optimize treatment of the patient with an acute coronary syndrome. Recognition that there is a great deal of interpatient variability in response to these antiplatelet therapies highlights the need for future research in this area.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:27Peripheral Artery Disease III: Interprofessional Care